Barda

US spends $290m stocking up on anti-radiation drug

17-Oct-2022 By Ben Hargreaves

US government agrees a deal with Amgen for the supply of Nplate, which is used to treat blood cell injuries due to radiation.

US BARDA contracts onshore manufacture of nerve agent treatment

03-Oct-2022 By Ben Hargreaves

Marinus will receive funds from BARDA to support the development of intravenous ganaxolone for the treatment of refractory status epilepticus.

bio 2022

Pandemic highlights need for supply chain visibility, partnerships

14-Jun-2022 By Jenni Spinner

During BIO International, US leaders shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises.

BARDA enlists Current Health in COVID-19 monitoring

22-Oct-2020 By Jenni Spinner

The collaboration will target signs of early deterioration in patients, and predict infection severity to let caregivers know when to escalate care.

NIH kicks off COVID-19 immune modulator trial

21-Oct-2020 By Jenni Spinner

The US agency has launched a large clinical trial to examine the viability of using immune modulators to treat patients hospitalized with COVID-19.

ATCC lands $250m from BARDA for COVID-19 services

06-Oct-2020 By Jenni Spinner

The contract, with a ceiling value of $250M and potential length of 10 years, will supplement the company’s ongoing support of virus-related work.

US FDA approves first treatment for smallpox to protect against bioterrorism

17-Jul-2018 By Ben Hargreaves

The first ever drug to treat smallpox has been approved by the US FDA, after having been created by SIGA Therapeutics in coordination with several US departments.